New opportunities in Haemophilia treatment: Efmoroctocog Alfa for patients with Haemophilia A

Q3 Nursing

Epidemiology Biostatistics and Public Health Pub Date : 2022-01-27 DOI:10.2427/13247

G. Calabrò, G. Castaman, G. Minno, S. Coretti, F. Rumi, J. Stojanović, D. Sacchini, C. Favaretti, A. Tagliaferri, A. Cicchetti

引用次数: 0

Abstract

Recently new opportunities are emerging for improving the way patients with Haemophilia A are treated. Among these opportunities, efmoroctocog alfa is a first-in-class recombinant factor VIII-Fc fusion protein (rFVIIIFc) produced by recombinant DNA technology with an extended half-life compared with conventional FVIII preparations. The available evidence coming from an Italian HTA report indicates that efmoroctocog alfa provides an effective alternative to conventional FVIII preparations (including standard rFVIIIs) for the management of Haemophilia A. Moreover, by reducing the frequency of injections required, it has the potential to reduce treatment burden, and hence improve adherence to prophylaxis and patient Quality-of-Life.

查看原文本刊更多论文

血友病治疗的新机遇:用于血友病A患者的Efmoroctocog Alfa

最近出现了改善A型血友病患者治疗方法的新机会。在这些机会中，efmoroctocog alfa是由重组DNA技术生产的一流重组因子VIII-Fc融合蛋白(rfviii - ifc)，与传统的FVIII制剂相比，其半衰期延长。来自意大利HTA报告的现有证据表明，efmoroctocog alfa为治疗a型血友病提供了传统FVIII制剂(包括标准rfviii制剂)的有效替代方案。此外，通过减少所需的注射频率，它有可能减轻治疗负担，从而提高对预防的依从性和患者的生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Epidemiology Biostatistics and Public Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

自引率

0.00%

发文量

期刊介绍： Epidemiology, Biostatistics, and Public Health (EBPH) is a multidisciplinary journal that has two broad aims: -To support the international public health community with publications on health service research, health care management, health policy, and health economics. -To strengthen the evidences on effective preventive interventions. -To advance public health methods, including biostatistics and epidemiology. EBPH welcomes submissions on all public health issues (including topics like eHealth, big data, personalized prevention, epidemiology and risk factors of chronic and infectious diseases); on basic and applied research in epidemiology; and in biostatistics methodology. Primary studies, systematic reviews, and meta-analyses are all welcome, as are research protocols for observational and experimental studies. EBPH aims to be a cross-discipline, international forum for scientific integration and evidence-based policymaking, combining the methodological aspects of epidemiology, biostatistics, and public health research with their practical applications.